Links:
Dr. John Cush @RheumNow( View Tweet )
AmericanJournalofHematology @AjHematology( View Tweet )
Links:
Dr. John Cush @RheumNow( View Tweet )
Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found.
In a multivariate analysis, having a high Disease Activity Score in 28 joints (DAS28) at baseline conferred twice the risk for
Links:
Dr. John Cush @RheumNow( View Tweet )
Chronic inflammatory disease (CID) patients are urged to receive the COVID-19 vaccines; but when a cohort of CID patients treated with immunosuppressive medications were given an mRNA-based SARS-CoV-2 vaccination, only those treated with glucocorticoids and B cell depleting therapies (BCDT)
Read Article
A new descriptive series shows an uncommon association between IgA vasculitis (IgAV) and inflammatory bowel diseases (IBD), with most cases interestingly arising after or during anti-TNF-ι therapy.
A retrospectively analysis of the GETAID and FVSG networks identified, 43 patients
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Links:
Dr. John Cush @RheumNow( View Tweet )
The American College of Rheumatology has issued an updated version of its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases following recent recommendations from the CDC that certain immunocompromised patients receive a third dose of an available mRNA
Read Article
A prospective study evaluated the value and associations with morning stiffness in patients with clinically suspect arthralgia, and found that the presence of morning stiffness increases the odds of inflammation (as detected by CRP and MRI synovitis).
Read Article
Among the factors that were associated with an increased risk for the development of rheumatic immune-related adverse events following cancer treatment with immune checkpoint inhibitors (ICIs) was the type of malignancy involved, a large case-control study found.
Read Article
Today, the U.S. Food and Drug Administration (FDA) approved the first COVID-19 vaccine, manufactured by Pfizer-BioNTech COVID-19 the vaccine, now marketed as Comirnaty (koe-mirâ-na-tee), is approved for the prevention of COVID-19 disease in individuals 16 years of age and older.
This
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis shows that the use of anakinra may reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia, especially highly elevated ferritin and C-reactive
Read Article
For organ transplant recipients, a third dose of Moderna's COVID-19 vaccine more than tripled the proportion with a sufficient antibody response, a randomized trial showed.
A third dose 2 months after the regular two-shot series produced a serologic response previously shown to confer
Read Article
The CDC had reported the Advisory Committee on Immunization Practices (ACIP) study of rare serious adverse events after COVID-19 vaccination and assert that the excessive morbidity and mortality from COVID-19 (and the protection afforded by vaccination) far exceeds the risk of rare safety
Read Article
AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. Â
Saphnelo theÂ
Read Article
Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (
Read Article
MMWR review of the risk of myocarditis and pericarditis reports a June 23, 2021 recommendation by the Advisory Committee on Immunization Practices that the benefits of COVID-19 vaccination clearly outweighed the risks of myocarditis after vaccination.Â
The COVID-19 vaccines fromÂ
Read Article
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Rituximab (RTX) has been in the news a lot lately; more surprisingly for its potential benefits in progressive systemic sclerosis (SSc).
Ebata and colleagues have published the results of a double-blind, randomised, placebo-controlled trial comparing intravenous RTX to placebo in 56 SSc
Links:
As many of you are aware, I have written and spoken on COVID-19 extensively over these past 20 months, and just last month wrote about the dangers of the delta variant. In July, things took an unexpected turn when I developed a breakthrough infection with the delta variant.
Read Post
